EVEREST MED (01952) saw its shares rise more than 8% during the morning trading session. At the time of writing, the stock was up 8.36%, trading at HK$37.58, with a turnover of HK$98.86 million. The company announced its annual results, revealing a 142% year-on-year increase in full-year revenue to RMB 1.707 billion. For the first time, it achieved profitability under non-IFRS measures, recording a profit of RMB 187 million, while its loss under International Financial Reporting Standards narrowed significantly by 71%. Operating cash flow also turned positive. The revenue growth was primarily driven by increased sales of Nefecon in already commercialized markets. EVEREST MED stated that 2026 will be a "year of execution" for its 2030 strategy and a critical period for achieving transformation. Nefecon is expected to remain the core growth engine for the company's sales revenue in 2026. The company plans to advance the inclusion of its products, such as IgAN and Vsetpin, in the national reimbursement drug list negotiations, accelerate the global clinical development of its self-developed pipeline, actively seek global partnership opportunities, and continue to promote in-licensing to further expand its coverage across therapeutic areas.
Comments